Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Venetoclax (Primary) ; Pomalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms CANOVA
  • Sponsors AbbVie; AbbVie Germany
  • Most Recent Events

    • 18 Sep 2019 Planned End Date changed from 27 Jan 2022 to 7 Jul 2022.
    • 24 Jun 2019 According to an AbbVie media release, U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on this trial.The partial clinical hold was removed following agreement on revisions of the study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria. Enrolment in the trial may resume as determined by each participant site based on the approved protocol.
    • 17 Jun 2019 Status changed from suspended to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top